Literature DB >> 2019007

Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation.

E J ter Borg1, G Horst, E Hummel, P C Limburg, C G Kallenberg.   

Abstract

We investigated whether rises in anti-double stranded DNA (anti-ds DNA) antibody levels prior to disease exacerbations of systemic lupus erythematosus (SLE) are part of a restricted immune response or merely the consequence of polyclonal B cell activation. As possible inducers of polyclonal B cell activation, we analyzed, in addition, the role of clinically apparent infections in relation to changes in levels of anti-ds DNA and disease exacerbations. We prospectively followed 72 lupus patients who were examined for disease activity and infections at least every 3 months by history and physical examination according to a protocol. Once a month, we measured levels of IgG-class antibodies to an unrelated recall antigen (tetanus toxoid), levels of IgG-class antibodies to a viral antigen (cytomegalovirus late antigens [CMV-LA]), levels of total immunoglobulins G and M, and levels of anti-ds DNA (by ELISA and Farr assay). Thirty-three exacerbations and 31 infections were observed during a follow-up period of an average of 18.5 patient months. Twenty-four out of the 27 exacerbations accompanied by a positive test for anti-ds DNA were preceded by a significant rise in anti-ds DNA: in 17 cases by ELISA and in 22 cases by Farr assay. These 24 rises in levels of anti-ds DNA prior to the exacerbation were paralleled by a significant rise in levels of IgG-class anti-tetanus antibodies in 8 cases, anti-CMV-LA antibodies in 9 cases, total IgG in 7 cases, and total IgM in 15 cases. Median rise in anti-ds DNA, as measured both by ELISA and Farr assay, exceeded the median rise in anti-tetanus antibodies, anti-CMV-LA antibodies, and total IgG and IgM (P less than 0.0001). Only one infection was recorded within a period of 3 months prior to an exacerbation, whereas infections never occurred within a period of 3 months prior to a rise in anti-ds DNA. We conclude that rises in anti-ds DNA prior to exacerbations of SLE are largely due to preferential activation of anti-ds DNA-specific B cells and not merely to polyclonal B cell hyperactivity. Clinically significant infections are not related to rises in levels of anti-ds DNA nor to the induction of exacerbations in SLE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019007     DOI: 10.1016/0090-1229(91)90086-p

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  10 in total

1.  B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation.

Authors:  P E Spronk; B T vd Gun; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

2.  Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

Authors:  K L Lim; A C Jones; N S Brown; R J Powell
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

3.  Host-microflora interaction in systemic lupus erythematosus (SLE): colonization resistance of the indigenous bacteria of the intestinal tract.

Authors:  H Z Apperloo-Renkema; H Bootsma; B I Mulder; C G Kallenberg; D van der Waaij
Journal:  Epidemiol Infect       Date:  1994-04       Impact factor: 2.451

4.  The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus.

Authors:  R W Burlingame; M L Boey; G Starkebaum; R L Rubin
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

5.  Urinary tract infections and lupus erythematosus.

Authors:  C Hidalgo-Tenorio; J Jiménez-Alonso; J de Dios Luna; M Tallada; A Martínez-Brocal; J Mario Sabio
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

6.  Microscopic polyangiitis and myasthenia gravis: the battle of Occam and Hickam.

Authors:  Michael V Holmes; Debajit Sen
Journal:  Clin Rheumatol       Date:  2007-04-06       Impact factor: 2.980

Review 7.  Predictors of pregnancy outcome in antiphospholipid syndrome: a review.

Authors:  Sara De Carolis; Angela Botta; Stefania Santucci; Serafina Garofalo; Carmelinda Martino; Alessandra Perrelli; Silvia Salvi; Sergio Ferrazzani; Leonardo Caforio; Giovanni Scambia
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

8.  Host-microflora interaction in systemic lupus erythematosus (SLE): circulating antibodies to the indigenous bacteria of the intestinal tract.

Authors:  H Z Apperloo-Renkema; H Bootsma; B I Mulder; C G Kallenberg; D van der Waaij
Journal:  Epidemiol Infect       Date:  1995-02       Impact factor: 2.451

Review 9.  Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Clin Dev Immunol       Date:  2012-06-14

10.  Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus.

Authors:  F Gmelig-Meyling; S Dawisha; A D Steinberg
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.